Status:
COMPLETED
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Neoplasm
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
A clinical study evaluates the safety, tolerability, and pharmacokinetics of ridaforolimus (MK-8669) in participants with locally advanced or metastatic solid tumors.
Eligibility Criteria
Inclusion
- Histologically - Or Cytologically- Confirmed Metastatic Or Locally Advanced Solid Tumors That Have Failed To Respond To Standard Therapy, Or For Which Adequate Standard Therapy Does Not Exist
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Adequate Organ Function
Exclusion
- Participant Who Has Had Chemotherapy, Radiotherapy, Or Biological Therapy Within 4 Weeks (6 Weeks For Nitrosoureas Or Mitomycin C) Prior To Registration
- Any central nervous system Metastasis Which Has Symptoms Or Requires Treatment
- Any Primary Central Nervous System Tumor
- Any Symptomatic Ascites Or Plural Effusion Which Requires Treatment
- A History Or Current Evidence Of Any Clinically Significant Disease That Might Confound The Results Of The Study, Complicate The Interpretation Of The Study Results, Interfere With The Participant's Participation, Or Pose An Additional Risk To The Participant
Key Trial Info
Start Date :
June 10 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 6 2009
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00694083
Start Date
June 10 2008
End Date
September 6 2009
Last Update
May 21 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.